tirzepatide vs semaglutide benefits caused roughly half as many patients to stop treatment because of gastrointestinal side effects as semaglutide. In the first major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide Tirzepatide vs Semaglutide: What's the

800.824.6016 Mon-Fri: 6:30 am - 5:00 pm PST Life-Assist has proudly served First Responders with emergency medical products and equipment since 1977

NICE guidance (NG28 for type 2 diabetes, TA875 for semaglutide 2.4 mg, and TA664 for liraglutide 3 mg) recommends regular monitoring of patients on GLP-1 therapy, with particular attention to tolerability and adverse effects

The peptide is easy to work with, following standard lab practices

Overall, many patients in both groups explored other weight-management treatment options within 12 months of stopping their initial GLP-1 injectable: Researchers say the findings underscore the importance of personalized, ongoing support for patients seeking obesity treatment even when they stop medication